Andrew Luber

592 total citations
22 papers, 395 citations indexed

About

Andrew Luber is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Andrew Luber has authored 22 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 7 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Andrew Luber's work include HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and Hepatitis B Virus Studies (4 papers). Andrew Luber is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and Hepatitis B Virus Studies (4 papers). Andrew Luber collaborates with scholars based in United States, Germany and Italy. Andrew Luber's co-authors include Courtney V. Fletcher, Giorgio Gatti, Rodolphe Garaffo, Richard M. W. Hoetelmans, Richard Haubrich, Michael Kurowski, Concepta Merry, David Back, Carlo Federico Perno and B. Joseph Guglielmo and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Andrew Luber

21 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Luber United States 9 315 167 120 43 40 22 395
Catherine Knupp United States 7 320 1.0× 232 1.4× 170 1.4× 45 1.0× 39 1.0× 9 471
Rosa Ruiz-Valderas Spain 12 342 1.1× 160 1.0× 189 1.6× 20 0.5× 52 1.3× 26 457
Yoninah Cramer United States 9 211 0.7× 98 0.6× 130 1.1× 27 0.6× 36 0.9× 17 345
Robin Dretler United States 9 231 0.7× 107 0.6× 202 1.7× 35 0.8× 19 0.5× 24 409
Patricia K. Mydlow United States 6 205 0.7× 87 0.5× 131 1.1× 27 0.6× 72 1.8× 7 367
L. Trentini Italy 11 257 0.8× 137 0.8× 78 0.7× 30 0.7× 53 1.3× 25 354
E.C.M. van Gorp Netherlands 9 262 0.8× 90 0.5× 50 0.4× 65 1.5× 68 1.7× 9 511
F. Borsa-Lebas France 10 136 0.4× 98 0.6× 103 0.9× 119 2.8× 32 0.8× 21 369
Minh Lê France 14 402 1.3× 186 1.1× 217 1.8× 29 0.7× 70 1.8× 53 644
Amelia S. Petry United States 7 367 1.2× 209 1.3× 119 1.0× 10 0.2× 78 1.9× 9 423

Countries citing papers authored by Andrew Luber

Since Specialization
Citations

This map shows the geographic impact of Andrew Luber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Luber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Luber more than expected).

Fields of papers citing papers by Andrew Luber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Luber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Luber. The network helps show where Andrew Luber may publish in the future.

Co-authorship network of co-authors of Andrew Luber

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Luber. A scholar is included among the top collaborators of Andrew Luber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Luber. Andrew Luber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hasanpourghadi, Mohadeseh, Zhiquan Xiang, Andrew Luber, et al.. (2024). A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses. JCI Insight. 9(21). 3 indexed citations
3.
4.
Ertl, Hildegund C.J., Sue Currie, & Andrew Luber. (2022). Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health. Frontiers in Immunology. 13. 985382–985382. 2 indexed citations
5.
6.
Luber, Andrew, et al.. (2012). CALIBRATION AND EPIPOLAR GEOMETRY OF GENERIC HETEROGENOUS CAMERA SYSTEMS. SHILAP Revista de lepidopterología. XXXIX-B5. 363–368. 2 indexed citations
7.
Luber, Andrew, et al.. (2012). ACCURACY EVALUATION OF STEREO CAMERA SYSTEMS WITH GENERIC CAMERA MODELS. SHILAP Revista de lepidopterología. XXXIX-B5. 375–380. 1 indexed citations
8.
Condoluci, David, et al.. (2008). CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.. PubMed. 18(8). 410–2. 1 indexed citations
9.
Ruane, Peter, Andrew Luber, Mary Beth Wire, et al.. (2007). Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 51(2). 560–565. 22 indexed citations
10.
Luber, Andrew. (2005). Genetic Barriers to Resistance and Impact on Clinical Response. Journal of the International AIDS Society. 7(1). 69–69. 40 indexed citations
11.
Luber, Andrew. (2005). Treatment strategies for highly treatment-experienced HIV-infected patients. Expert Review of Anti-infective Therapy. 3(5). 815–823. 3 indexed citations
12.
Luber, Andrew. (2005). Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.. PubMed. 15(12). 692–5, 698. 10 indexed citations
13.
Ruane, Peter & Andrew Luber. (2004). K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.. PubMed. 6(2). 31–31. 9 indexed citations
14.
Back, David, Giorgio Gatti, Courtney V. Fletcher, et al.. (2002). Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 16. S5–S37. 147 indexed citations
15.
Becker, Stephen, Alvan Fisher, Charles Flexner, et al.. (2001). Pharmacokinetic Parameters of Protease Inhibitors and the Cmin/IC50 Ratio: Call for Consensus. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(2). 210–211. 2 indexed citations
16.
Guglielmo, B. Joseph, et al.. (2000). Ceftriaxone Therapy for Staphylococcal Osteomyelitis: A Review. Clinical Infectious Diseases. 30(1). 205–207. 40 indexed citations
17.
Luber, Andrew. (1999). Risk factors for amphotericin B- induced nephrotoxicity. Journal of Antimicrobial Chemotherapy. 43(2). 267–271. 75 indexed citations
18.
Guglielmo, B. Joseph, Andrew Luber, Robin L. Corelli, John F. Flaherty, & Robert A. Jacobs. (1999). Prevention of adverse events in hospitalized patients using an antimicrobial review program.. PubMed. 171(3). 159–62. 2 indexed citations
19.
Luber, Andrew, et al.. (1996). Hypothermia Following the Intravenous Administration of Amphotericin B. Clinical Infectious Diseases. 23(5). 1187–1188. 5 indexed citations
20.
Luber, Andrew & John F. Flaherty. (1996). Famciclovir for Treatment of Herpesvirus Infections. Annals of Pharmacotherapy. 30(9). 978–985. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Knupp Breakdown of academic impact, for papers by Rosa Ruiz-Valderas Breakdown of academic impact, for papers by Yoninah Cramer Breakdown of academic impact, for papers by Robin Dretler Breakdown of academic impact, for papers by Patricia K. Mydlow Breakdown of academic impact, for papers by L. Trentini Breakdown of academic impact, for papers by E.C.M. van Gorp Breakdown of academic impact, for papers by F. Borsa-Lebas Breakdown of academic impact, for papers by Minh Lê Breakdown of academic impact, for papers by Amelia S. Petry
Rankless by CCL
2026